| 000 | 01841 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513160852.0 | ||
| 264 | 0 | _c19990421 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1046/j.1365-2036.1998.00427.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGreen, J R | |
| 245 | 0 | 0 |
_aMaintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cDec 1998 |
||
| 300 |
_a1207-16 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAminosalicylic Acids _xadministration & dosage |
| 650 | 0 | 4 |
_aAnti-Ulcer Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aColitis, Ulcerative _xdrug therapy |
| 650 | 0 | 4 |
_aDelayed-Action Preparations _xpharmacokinetics |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeadache _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesalamine _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPhenylhydrazines |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aGibson, J A | |
| 700 | 1 | _aKerr, G D | |
| 700 | 1 | _aSwarbrick, E T | |
| 700 | 1 | _aLobo, A J | |
| 700 | 1 | _aHoldsworth, C D | |
| 700 | 1 | _aCrowe, J P | |
| 700 | 1 | _aSchofield, K J | |
| 700 | 1 | _aTaylor, M D | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 12 _gno. 12 _gp. 1207-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2036.1998.00427.x _zAvailable from publisher's website |
| 999 |
_c9843917 _d9843917 |
||